Excellencies - Pneumologies

Clinical Studies

Our O.U. adheres to many experimental clinical studies on the use of new drugs in the treatment of various rare and non-rare diseases.
This gives patients access to the most innovative drugs on the market.

PULMONARY FIBROSIS

STUDIO CVAY736 NOVARTIS
TITLE: Randomized, placebo-controlled, multicenter, blind trial for subject, investigator and sponsor to evaluate the efficacy, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis.

Activation phase study

BIOGEN STUDY
TITLE: Randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of BG00011 in patients with idiopathic pulmonary fibrosis.

Activation phase study

NITTO STUDY:
TITLE: Randomised, double-blind, placebo-controlled phase 2 trial to assess the safety, tolerability, biological activity and pharmacokinetics of nd-l02-s0201 in subjects with idiopathic pulmonary fibrosis (IPF).

Activation phase study

LAM

STUDY Creation and drafting of the protocol: U.O. PNEUMOLOGIA – OSPEDALE SAN GIUSEPPE
TITLE: “Pilot study on nintedanib in Lymphangioleiomatosis (LAM)” Patients who have not benefited from sirolimus therapy or have not tolerated it, or patients who have not taken any therapy for LAM and who meet the criteria for inclusion, may participate in this study.

Active study with open recruitment

PULMONARY EMBOLISM

STUDY COPE
TITLE: Contemporary Clinical Management of Acute Pulmonary Embolism – COPE study.

Active study with open enrolment